Regulatory writing demands flawless execution of Clinical Study Reports, Common Technical Documents, and FDA submissions. Precision in adverse event narratives, protocol documentation, and drug labeling directly impacts approval timelines.

Our assessments evaluate ICH E6 terminology, CFR citation accuracy, and CTD formatting proficiency. The test identifies writers who can navigate FDA guidance documents and execute compliance-grade documentation without regulatory queries.

Illustrative scenario

Misclassified Adverse Event Severity Delays NDA Submission by Six Months

A regulatory writer incorrectly classified serious adverse events as severe in multiple CSR narratives, creating inconsistencies across the New Drug Application modules. The FDA issued a Complete Response Letter requiring resubmission of corrected safety data, delaying market approval and costing $2.8 million in lost revenue.

A composite example of a failure mode that is common in Regulatory Writing. It is not an account of a real client engagement and no real organisation is described.

Documents You'll Be Testing

Clinical Study Report
Common Technical Document Module 2
Investigational New Drug Application
Periodic Safety Update Report
Risk Evaluation Mitigation Strategy
New Drug Application Module 1

Avoid These Common Editorial Mistakes

Inconsistent adverse event terminology

FDA information requests delaying approval timelines and requiring costly resubmission cycles

Incorrect ICH guideline citations

Regulatory queries questioning study conduct compliance and data integrity assessments

CTD cross-reference formatting errors

Module linking failures preventing reviewers from accessing supporting documentation efficiently

Protocol deviation misclassification

GCP compliance questions triggering site inspection requirements and submission hold decisions

Drug labeling inconsistencies

Complete Response Letters requiring comprehensive safety update reanalysis and resubmission preparation

Master These Key Terms

serious vs severe
drug substance vs drug product
protocol deviation vs protocol violation
investigational medicinal product vs investigational new drug
causality assessment vs causal relationship

Smart Hiring Strategies

Prioritize candidates demonstrating mastery of ICH guidelines, FDA 21 CFR requirements, and CTD formatting standards. Test for precision with adverse event terminology, clinical endpoint definitions, and pharmacovigilance vocabulary.

FDA reviewers scrutinize every submission detail, with terminology errors triggering costly information requests that delay market entry. Pre-screening ensures regulatory writers can produce compliance-grade documentation from day one.

Frequently Asked Questions

How do I assess if candidates understand FDA submission requirements without being a regulatory expert myself? ↓
Our tests evaluate candidates' ability to apply standard regulatory terminology and formatting consistently. You don't need technical expertise—the assessment identifies writers who can follow FDA guidance documents and maintain compliance-grade accuracy in their documentation.
What's the typical learning curve for regulatory writing hires, and how does testing help? ↓
New regulatory writers typically require 6-8 months to master ICH guidelines and FDA requirements. Pre-screening identifies candidates with existing regulatory vocabulary and formatting skills, reducing training time and minimizing costly submission errors during their learning period.
Should I prioritize candidates with clinical research experience or those with strong general medical writing skills? ↓
Regulatory writing demands specific knowledge of FDA guidance documents and ICH terminology that differs from general medical writing. Our assessments help identify candidates who understand regulatory-specific concepts like CTD formatting and pharmacovigilance terminology, regardless of their background.
How can I evaluate candidates' attention to detail for documents I can't personally review for technical accuracy? ↓
Our tests simulate real regulatory writing challenges, including adverse event classification and ICH guideline application. The scoring system identifies candidates who maintain consistency and precision under regulatory documentation standards, providing objective measurement of detail-oriented performance.
What red flags should I watch for when hiring regulatory writers, and how does testing reveal them? ↓
Key warning signs include terminology inconsistency, inability to distinguish regulatory-specific concepts, and formatting errors that could trigger FDA queries. Our assessments reveal these issues through standardized scenarios that mirror actual submission requirements and regulatory review processes.